Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus (T2DM)
A Study of an Existing Database to Assess the Treatment Persistence to Basal Insulin in Type 2 Diabetes Mellitus Patients in a Structured Patient Education Program in India
The aim of this study is to analyze data from an existing database named SAATH-7 Star, in order to assess the treatment persistence to basal insulin in Type 2 diabetes patients who had been enrolled in the SAATH-7 Star structured…
- Trial name
- PERSISTENT (NCT05628090)
- Where
- France
- Volunteers
- 47,885 people
- Sponsor
- Sanofi
Chronic Kidney Disease
A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes
The purpose of this study is to determine if selected renal cells, obtained by biopsy from a patient with chronic kidney disease (CKD) and Type 2 Diabetes (i.e., autologous cells) can be safely implanted back into the patient.
- Trial name
- NCT02008851
- Testing
- Neo-kidney augment
- Where
- 5 sites in United States
- Volunteers
- 1 people
- Sponsor
- Tengion
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice
This study is to investigate the effects of Fiasp®, a mealtime insulin, in patients with diabetes mellitus. The purpose of this study is to collect information about Fiasp®, which is prescribed to the participants by their…
- Trial name
- NCT03987802
- Testing
- Faster-acting insulin aspart
- Where
- 36 sites in India
- Volunteers
- 42 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Beta Cell Relieving and Cardiovascular Protective Effects of LANTUS Treatment in Type 2 Diabetes Patients
The purpose of this phase IV clinical trial is to investigate the effect of Insulin glargine + metformin treatment vs. sulfonylurea + metformin treatment vs. DPP-4 + metformin treatment vs.
- Trial name
- NCT01206712
- Where
- Germany
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- ikfe-CRO GmbH
Type 2 Diabetes Mellitus
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Pioglitazone in Type 2 Diabetic Patients
This study is to evaluate the efficacy and safety after concomitant administration of ASP1941 and pioglitazone in patients with diabetes mellitus.
- Trial name
- NCT01225081
- Testing
- ipragliflozin, Pioglitazone
- Where
- 7 sites in Japan
- Volunteers
- 152 people
- Sponsor
- Astellas Pharma Inc
Diabetes Mellitus, Type 2
A Study of LY3209590 in Japanese Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the safety of a study drug known as LY3209590 in Japanese participants with type 2 diabetes. Side effects and tolerability will be documented.
- Trial name
- NCT04276428
- Testing
- LY3209590, Insulin Degludec
- Where
- 3 sites in Japan
- Volunteers
- 28 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
The Mobile Diabetes Mgmt. Study With Type 2 Diabetes
A Multi-center, Randomized, Parallel, Open Clinical Trial to Evaluate the Glycemic Control Effect of the Mobile Healthcare Service Using U-Healthcare Clinical Decision Support System (CDSS) and U-Healthcare Gateway in Patients…
- Trial name
- NCT02451631
- Testing
- Traditional care with paper, Health-on G App. + Physician Web
- Where
- 3 sites in South Korea
- Volunteers
- 184 people
- Sponsor
- Healthconnect
Improved Glycemic Control in Patients With Type 2 Diabetes
A Trial of HR17031 Injection With Renal Insufficiency
This study used a single-dose, open design to compare the pharmacokinetics of subjects with mild, moderate and severe renal insufficiency and end-stage renal disease and subjects with normal renal function.
- Trial name
- NCT05292495
- Testing
- HR17031 injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
T2DM
Efficacy and Safety of Pioglitazone Combination Therapy in Type 2 Diabetes Patients on a Background of Empagliflozin With Metformin
Phase 3 study to assess the Efficacy and Safety of CT-L03-301 in Type 2 Diabetes Patients with Insufficient Glycemic Control with Metformin and Empagliflozin Combination Therapy.
- Trial name
- CT-L03 (NCT06571591)
- Testing
- CT-L03 Group 1, CT-L03 Group 2, Empagliflozin
- Where
- South Korea
- Volunteers
- 606 people
- Sponsor
- Celltrion
Type 2 Diabetes Mellitus
A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes
This study will explore the effect of exenatide (given twice a day) versus placebo (given twice a day) treatment on change in mean 24-hour heart rate over a 12 week period of drug exposure in patients with type 2 diabetes.
- Trial name
- NCT00516074
- Testing
- exenatide
- Where
- 6 sites in Canada, Netherlands
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
NASH, NASH - Nonalcoholic Steatohepatitis
Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH
A randomized, multi-center study evaluating MET409 (50 mg) alone or in combination with empagliflozin (10 mg) for 12 weeks. Assignment to MET409 will be double-blind and placebo-controlled.
- Conditions
- NASH, NASH - Nonalcoholic Steatohepatitis, Type 2 Diabetes, Diabetes Type 2
- Trial name
- NCT04702490
- Testing
- MET409 Active, Empagliflozin
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Metacrine, Inc.
Type 2 Diabetes Mellitus, Liver Dysfunction
Pharmacokinetic and Pharmacodynamic Study of Glufast Tablets 10mg(Mitiglinide)
This clinical trial is designed to assess the effect of hepatic impairment on the pharmacokinetic and pharmacodynamic of glufast tablets 10 mg.
- Trial name
- NCT04349696
- Testing
- Mitiglinide
- Where
- 2 sites in Taiwan
- Volunteers
- 16 people
- Sponsor
- Orient Europharma Co., Ltd.
Diabetes Mellitus, Type 2
Risk of Acute Liver Failure Among Patients With Type 2 Diabetes Exposed to Oral Antidiabetic Treatments
The purpose of this study is to compare the incidence of hospitalization with acute liver failure among patients with type 2 diabetes who are new users of Saxagliptin and those who are new users of other oral antidiabetic drugs.
- Trial name
- NCT01086293
- Volunteers
- 113,505 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
Observational Study to Observe the Safety of NovoMix® 30 Treatment in Patients With Type 2 Diabetes
This study is conducted in Europe. The study aims to observe the incidence of serious adverse drug reactions in patients with type 2 diabetes during NovoMix® 30 treatment.
- Trial name
- NCT00729898
- Testing
- biphasic insulin aspart 30
- Where
- 2 sites in Norway, Sweden
- Volunteers
- 243 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Treatment Use of Generex Oral-lyn™ in Patients With Diabetes
The objective of this Treatment IND protocol is to provide Generex Oral-lyn™ to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for treatment of…
- Trial name
- NCT00948493
- Testing
- Buccal insulin spray
- Sponsor
- Generex Biotechnology Corp.
Type 2 Diabetes
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
The purpose of this study is to evaluate the efficacy and safety of IBI362 in Chinese patients with Type 2 Diabetes.
- Trial name
- NCT04965506
- Testing
- IBI362, Dulaglutide
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Diabetes Mellitus, Type 2
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
Empagliflozin (Jardiance), a highly potent and selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2), was approved in Europe in May 2014 for the treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic…
- Trial name
- NCT02864914
- Testing
- Empagliflozin, DPP-4 inhibitors
- Where
- United Kingdom
- Volunteers
- 333,580 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE)
The purpose of this study is to examine the effectiveness and safety of insulin lispro protamine suspension (ILPS) as compared to insulin glargine as basal insulin therapy in adults with type 2 diabetes.
- Trial name
- IOPE (NCT00510952)
- Testing
- Insulin Lispro Protamine Suspension, Insulin Glargine
- Where
- 17 sites in United States, Brazil and 2 more
- Volunteers
- 471 people
- Sponsor
- Eli Lilly and Company
Chronic Stable Heart Failure
Efficacy and Safety of TRC041266 in Patients With Heart Failure, LVEF ≥40%, Diastolic Dysfunction and Type 2 Diabetes Mellitus
This study will be conducted as a randomized, multi-centre, double-blind, parallel-group, placebo-controlled study in patients receiving SoC therapy.
- Trial name
- NCT04507347
- Testing
- TRC041266
- Sponsor
- Torrent Pharmaceuticals Limited
Type 2 Diabetes Mellitus
Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus
This extension study was designed to evaluate the safety and efficacy of Canagliflozin (TA-7284) in combination with Insulin in patients with type 2 Diabetes Mellitus.
- Trial name
- NCT02622113
- Testing
- Canagliflozin (TA-7284), Insulin
- Where
- 7 sites in Japan
- Volunteers
- 139 people
- Sponsor
- Tanabe Pharma Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.